Mizuho Securities Reiterates Revance Therapeutic (RVNC) at Buy, "Encouraged by the Traction Gaining", "Assume Daxi Will Get Approved and Set Stage for Significant Upside"
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $26.00 price target on Revance Therapeutic (NASDAQ: RVNC), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
